EGFR and non-small cell lung carcinoma: Overall, little had changed in terms of EGFR mutation testing: in 2016, testing before first-line therapy was requested in 80% (excluding China) of patients; in 2015 that figure was 81% of patients with stage IIIb/IV NSCLC.18 Testing frequency differed between regions.